Manufactures a range of amines and specialty chemicals — including ethylenediamine-based products (DETA, TETA, PIP, AEEA, AEP), N-methyl morpholine, acetonitrile, hydrogen cyanide, sodium cyanide, EDTA, dimethyl ether (DME) and battery-grade chemicals — selling primarily to pharmaceutical, agrochemical, solvents and battery industries. The Amines & Speciality Chemicals segment brought in Rs 1,415.69 crore of revenue in the period to 31 March 2026 (97.1% of segment revenue), with EBIT of Rs 225.25 crore. A separate Hotel Division contributed Rs 35.70 crore (2.4% of segment revenue) and EBIT of Rs 9.37 crore. Operations run across 6 manufacturing plants serving 55 countries, with exports at 14.3% of the business. India's first commercial 100,000 TPA DME plant was commissioned in Q1 FY27, a 5,000 TPA N-methyl morpholine expansion is in progress, and subsidiary Balaji Specialty Chemicals is executing a Rs 750 crore phased build-out (Unit-I for EDA-based products in H1 FY27; Unit-II for HCN, NaCN, EDTA in Q4 FY27). Raw materials are the dominant cost at 56.9% of revenue, followed by other operating expenses at 19.6% and employee costs at 5.9%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Amines & Speciality Chemicals (97%), Hotel Division (2%). Asset-heavy specialty chemicals manufacturer with a small hotel side-business
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2,320 | 2,355 | 1,642 | 1,397 | 1,425 |
| EBITDA (ex other income) | 630 | 609 | 324 | 232 | 265 |
| margin % | 27.2 | 25.9 | 19.7 | 16.6 | 18.6 |
| Owners' profit | 368 | 326 | 200 | 158 | 169 |
| EPS, as reported (₹) | 113.71 | 100.47 | 63.22 | 48.62 | 51.60 |
| ROE % · ROCE % | 31.8 · 40.9 | 23.9 · 31.9 | 12.3 · 15.4 | 7.9 · 10.2 | 7.9 · 10.2 |
| Debt / equity (x) | 0.06 | 0.03 | 0.01 | 0.01 | 0.06 |
| Cash from operations | 232 | 382 | 220 | 255 | 184 |
| Capex | (148) | (120) | (253) | (186) | (370) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 347 | 313 | 353 | 358 | 341 | 331 | 395 | 456 |
| Profit before tax | 57 | 41 | 54 | 49 | 52 | 46 | 86 | 106 |
| Net profit | 41 | 31 | 40 | 76 | 37 | 31 | 65 | 78 |
| EPS (₹) | 12.65 | 10.24 | 12.36 | 11.73 | 10.67 | 9.49 | 19.99 | 23.13 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Amines & Speciality Chemicals | 394 | 27.0 |
| Hotel Division | 18 | 1.2 |
| Unallocated | 4 | 0.3 |
| Amines & Speciality chemicals | 325 | 22.3 |
| AMINES AND SPECIALITY CHEMICALS | 698 | 47.9 |
| HOTEL DIVISION | 18 | 1.2 |
| UNALLOCATED | 2 | 0.1 |
| Total, before eliminations | 1,458 | 100.0 |
| Company | M.cap ₹ cr | P/E |
|---|
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 2 Sept 2026 · Newspaper Ad on Special Window for Physical Share Demat | compliance | minimal | — | — |
| 17 Aug 2026 · Plant visit and investor meet scheduled for August 25 in Solapur | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Balaji Amines to hold virtual group meeting with analysts on 21 August 2026 | board shareholder meetings | low | — | — |
| 29 Jul 2026 · Balaji Amines Q1 FY27: Revenue up 26% YoY, PAT more than doubles on margin gains | investor communications | medium | — | — |
| 28 Jul 2026 · Newspaper publication of Q1 FY27 unaudited results | compliance | minimal | — | — |
| 27 Jul 2026 · Balaji Amines Q1FY27 consol PAT doubles YoY to Rs 78 Cr | compliance | low | — | — |
| 27 Jul 2026 · Q1 FY27 Results: Revenue up 32 percent, PAT jumps 81 percent YoY (Standalone) | results | high | — | — |
| 27 Jul 2026 · Balaji Amines Q1 FY27: Revenue up 32%, PAT up 81% YoY | results | high | — | — |
| 17 Jul 2026 · Board meeting on 27 July 2026 to consider Q1 FY27 results | results | low | — | — |
| 13 Jul 2026 · Balaji Amines 38th AGM: All 4 Resolutions Passed, Dividend of Rs 11 Per Share Declared | board shareholder meetings | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| P/B |
|---|
| EV/EBITDA |
|---|
| ROE % |
|---|
| ROCE % |
|---|
| Rev CAGR 5y % |
|---|
| EBITDA m. % |
|---|
| PIDILITE INDUSTRIES LTD | 1,59,479 | 60.2 | 14.43 | 42.3 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 73,583 | 34.0 | 5.24 | 22.7 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 52,514 | 85.7 | 6.64 | 41.5 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,836 | 55.4 | 11.03 | 39.5 | 16.7 | 16.4 | 23.0 | 37.5 |
| AETHER INDUSTRIES LIMITED | 22,229 | 94.3 | 9.05 | 60.4 | 8.9 | 11.4 | — | 33.8 |
| DEEPAK NITRITE LTD | 21,769 | 27.8 | 3.71 | 22.4 | 9.4 | 10.2 | 12.6 | 21.5 |
| ATUL LTD | 18,401 | 23.1 | 2.92 | 14.9 | 10.9 | 13.3 | 10.9 | 23.1 |
| AARTI INDUSTRIES LTD | 17,846 | 33.6 | 3.00 | 18.8 | 7.0 | 4.4 | 13.0 | 16.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 36.1 | 23.4 | 72 of 103 | 30% |
| P/B | 3.4 | 2.9 | 62 of 99 | 38% |
| ROCE | 9.9 | 10.3 | 56 of 108 | 49% |
| ROE | 7.9 | 8.1 | 53 of 101 | 48% |
| Debt / Equity | 0.1 | 0.2 | 41 of 101 | 60% |
| EBITDA margin | 26.6 | 15.5 | 17 of 99 | 84% |
| Revenue growth | 27.2 | 24.4 | 39 of 94 | 59% |
| Profit growth | 2.8 | 55.1 | 72 of 92 | 22% |
| Market cap | 7397 | 732 | 20 of 107 | 82% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
